# EDGAR Filing Document

**Accession Number:** 0001808898
**File Stem:** 0001193125-25-220122
**Filing Date:** 2025-9
**Character Count:** 2131
**Document Hash:** 2d0a9c426cda9c7bb8ff1d04e71a6249
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-220122.hdr.sgml**: 20260128

**ACCESSION NUMBER**: 0001193125-25-220122

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250926

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Benitec Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001808898
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 3940 TRUST WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545
- **BUSINESS PHONE:** (510) 780-0819

**MAIL ADDRESS:**
- **STREET 1:** 3940 TRUST WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545

**BENITEC BIOPHARMA INC.**

3940 Trust Way

Hayward, California 94545

September 26, 2025

**VIA EDGAR**

Joshua Gorsky<br>Joe McCann

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Benitec Biopharma Inc.** |
|  | **Registration Statement on Form S-3 (File No. 333-290455)** |

---

Dear Mr. Gorsky and Mr. McCann:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-290455) so that it may become effective at 4:00 p.m. Eastern Time on September 29, 2025, or as soon thereafter as practicable.

Very truly yours,

---

| | | |
|:---|:---|:---|
| **BENITEC BIOPHARMA INC.** | **BENITEC BIOPHARMA INC.** | **BENITEC BIOPHARMA INC.** |
| By:  | /s/ Dr. Jerel Banks | /s/ Dr. Jerel Banks |
|  | Name: | Dr. Jerel Banks |
|  | Title: | Chief Executive Officer |

---

cc: Matt O'Loughlin, Proskauer Rose LLP

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Louis Rambo, Proskauer Rose LLP

------